



PROGRAMME

Global Forum on Renal and Bladder Cancer


26-28 November 2024 Vienna Marriott Hotel, Austria

renalc.org | bladdr.org









Welcome

Dear colleagues, dear friends,

Congratulations, you've made it to Vienna, the destination of your RENALC and BLADDR journeys! Some say the journey is more important than the destination. We say: they are equally important. The journeys with the patient case challanges were the ideal warm-up for the real workout: RENALC 2024 and BLADDR 2024.

For 2024, our focus remains on identifying the impact that new data and treatments have on best practice, and how to translate these into your daily clinical practice in order to improve patient management.

To achieve this, we will bring together an international multidisciplinary top faculty to present the data along with a panel of experts who will shape these data into recommendations on the spot, in a new discussion-based format where you will also have a voice!

Yes, in these meetings, you will:

- ightarrow get a full update on renal cancer and bladder cancer
- ightarrow learn from keynote speakers about the major clinical advances for your practice
- \rightarrow get the chance to interact and challenge the expert panel during case discussions
- ightarrow share a coffee and your views with top leaders

Join the discussions and participate in the lively debates! Ready, set, go!

Welcome to Vienna!



Organising committee



Philippe Barthélémy Medical Oncology Strasbourg, France



Manuela Schmidinger Medical Oncology Vienna, Austria



Bernadett Szabados Urology London, UK

Faculty

Philippe Barthélémy Medical Oncology Strasbourg, France

Axel BexUrology London, UK

Saeed Dabestani

Urology Malmö, Sweden @DrDabestani

Ignacio Duran

Medical Oncology Santander, Spain @nachoduranm

Petros Grivas

Medical Oncology Seattle, USA @PGrivasMDPhD

Géraldine Pignot

Urology Marseille, France @PignotG

Renate Pichler

Urology Innsbruck, Austria @Renate_Pichler

Lisa Pickering

Medical Oncology London, UK @lisapic

Manuela Schmidinger

Medical Oncology Vienna, Austria @schmidingerRCC

Bernadett Szabados

Urology London, UK @b_szabados

Tuesday 26 November

13:00	Official opening Manuela Schmidinger, Philippe Barthélémy
13:15	Congress highlights with impact on clinical practice Moderator: Axel Bex
	Localised RCC - Bernadett Szabados
	Metastatic RCC - Ignacio Duran
	Discussion and Q&A
13:45	High-risk RCC after nephrectomy and oligometastatic RCC Moderators: Ignacio Duran, Lisa Pickering
	Risk assessment of post-nephrectomy patients - Philippe Barthélémy
	Debate: Weighing the pros and cons of adjuvant therapy - Saeed Dabestani, Manuela Schmidinger
	Cytoreductive nephrectomy: the history - Saeed Dabestani
	To operate or not? Debate on deferred cytoreductive nephrectomy - Axel Bex, Géraldine Pignot
	Discussion and Q&A
15:15	Break
15:45	Case discussion session: Selecting treatment for metastatic RCC Moderators: Philippe Barthélémy, Bernadett Szabados Panel onsite: Philippe Barthélémy, Ignacio Duran, Renate Pichler, Lisa Pickering, Manuela Schmidinger, Bernadett Szabados Panel not onsite: Amarnath Challapalli, Daan De Maeseneer, Javier Puente
	Mirrors of Medicine – case-based approach - Petros Grivas
	Case presentation - Petros Grivas
	Selecting first-line treatment for advanced clear-cell RCC - Manuela Schmidinger
	Treatment options for patients with metastatic papillary RCC - Lisa Pickering
	Lisa Ficketting
	Panel discussion and Q&A
17:15	
17:15	Panel discussion and Q&A Looking ahead: RCC management in 2025
17:15	Panel discussion and Q&A Looking ahead: RCC management in 2025 Moderator: Saeed Dabestani
17:15	Panel discussion and Q&A Looking ahead: RCC management in 2025 Moderator: Saeed Dabestani View of the urologist - Axel Bex

RENALC thanks its sponsors and partners


Principal sponsor



Silver sponsor



Bronze sponsors







Partners













Notes

Global organising committee



Ananya Choudhury Clinical Oncology Manchester, UK



Maria De Santis **Uro-Oncology** Berlin, Germany



Badrinath Konety Urology Minneapolis, USA

Local organising committee



Eva Compérat Pathology Vienna, Austria



Kilian Gust Urology Vienna, Austria



Dora Niedersüß-Beke Medical Oncology Vienna, Austria

Faculty

Vérane Achard

Radiation Oncology Fribourg, Switzerland @Achard_Verane

Dirk Beversdorff

Radiology Hamburg, Germany

Ananya Choudhury

Clinical Oncology Manchester, UK @achoud72

Eva Compérat

Pathology Vienna, Austria @evacomperat

Marco de Felice

Patient representative Vienna, Austria

Daan De Maeseneer

Medical Oncology Bruges & Ghent, Belgium @daandm

Ben-Max de Ruiter

Urology Alkmaar & Amsterdam, the Netherlands

Maria De Santis

Medical Oncology Berlin, Germany @mdesantis234

Ignacio Durán

Medical Oncology Santander, Spain @nachoduranm

Petros Grivas

Medical Oncology Seattle, USA @PGrivasMDPhD

Kilian Gust

Urology Vienna, Austria @KilianGust

Peter Hoskin

Clinical Oncology Northwood & Manchester & London, UK

Rob Jones

Medical Oncology Glasgow, UK

Badrinath Konety

Urology Minneapolis, US @bkonety

Suma Konety

Cardio-oncology Minneapolis, US

Cédric Lebâcle

Urology Paris, France @CLebacle

Laura Mertens

Urology Amsterdam, The Netherlands @LAUrology NL

Dora Niedersüß-Beke

Medical Oncology Vienna, Austria

Renate Pichler

Urology Innsbruck, Austria @Renate_Pichler

Géraldine Pignot

Urology Marseille, France @PignotG

Daniele Raggi

Medical Oncology London, UK @DanieleRaggi83

Celena Scheede-Bergdahl (virtual)

Physiotherapy Montreal, Canada @CelenaBergdahl

Bernadett Szabados

Urology London, UK @b_szabados

Gunhild von Amsberg

Medical Oncology Hamburg, Germany

Fred Witjes

Uroloay Nijmegen, the Netherlands

Wednesday 27 November

09:00	Official opening Eva Compérat, Kilian Gust
09:15	Staging, monitoring and response prediction: utility or futility of novel approaches
	Moderators: Ananya Choudhury, Fred Witjes
	Role of AI for diagnosis and monitoring bladder cancer - Eva Compérat
	How can mpMRI change management of patients with NMIBC or MIBC? - Dirk Beyersdorff
	Can AI drive treatment decision-making in NMIBC? - Badrinath Konety
	Discussion and Q&A
10:10	MIBC congress highlights from ESMO Moderator: Renate Pichler Presenter: Maria De Santis
10:40	Debate: the role of ctDNA to manage MIBC in the adjuvant setting
	Moderator: Daniele Raggi
	Presenters: Petros Grivas, Bernadett Szabados
11:05	Break
11:30	Case discussion session: NMIBC Moderators: Maria De Santis, Renate Pichler Panel: Ben-Max de Ruiter, Maria De Santis, Petros Grivas, Kilian Gust, Badrinath Konety, Cédric Lebâcle, Laura Mertens, Renate Pichler, Géraldine Pignot, Fred Witjes
	Mirrors of Medicine – case-based approach - Petros Grivas
	Case presentation - Daan De Maeseneer
	Debate: Are we ready to de-intensify treatment and surveillance in low- grade NMIBC? - Kilian Gust, Cédric Lebâcle
	High-risk BCG-naive NMIBC: should we stick to BCG? - Ben-Max de Ruiter
	High-risk BCG-unresponsive NMIBC: are we ready to delay/avoid RC? - Petros Grivas
	Panel discussion and Q&A
13:00	Lunch
14:00	RC and neobladder
	Moderators: Dora Niedersüß-Beke, Badrinath Konety
	Prehabilitation programme - Celena Scheede-Bergdahl (virtual)
	Patient selection for neobladder - Laura Mertens
	Patient testimony on living with a neobladder - Marco de Felice
	Panel discussion and Q&A

Wednesday 27 November

15:00	First-line treatment for advanced UCa: balancing between efficacy, safety, patient characteristics and QoL Moderator: Dora Niedersüß-Beke Presenter: Gunhild von Amsberg
15:30	Update lecture: Immunotherapy and cardiac complications Moderator: Gunhild von Amsberg Presenter: Suma Konety
16:00	Break
16:30	Case discussion session: MIBC Moderators: Ben-Max de Ruiter, Dirk Beyersdorff Panel: Ananya Choudhury, Ben-Max de Ruiter, Ignacio Duran, Peter Hoskin, Rob Jones, Badrinath Konety, Cédric Lebâcle, Daniele Raggi, Gunhild von Amsberg, Fred Witjes
	Case presentation - Daan De Maeseneer
	Personalised TMT - Peter Hoskin
	New combinations and concepts of (neo)adjuvant therapy to RC or TMT for MIBC - Ignacio Duran
	Debate: Withholding radical treatment after CR with neoadjuvant treatment: future-talk or not? - Petros Grivas, Fred Witjes
	Panel discussion and Q&A
18:00	End of day 1 & reception



Thursday 28 November

08:55	Opening day 2
09:00	Practical surgical questions Moderator: Cédric Lebâcle
	Practical aspects of intravesical instillation - Fred Witjes
	The optimal TURBT - Ben-Max de Ruiter
	The impact of RC on sexual function/experience - Géraldine Pignot
	Q&A
09:45	Looking ahead: BCa management in 2025 Moderator: Badrinath Konety
	View of the urologist - Kilian Gust
	View of the radiation oncologist - Vérane Achard
	View of the medical oncologist - Rob Jones
	Discussion and Q&A
10:30	Multidisciplinary discussion on molecular testing Moderator: Bernadett Szabados Panel: Eva Compérat, Maria De Santis
11:00	Break
11:30	Case discussion session: metastatic UCa Moderators: Peter Hoskin, Bernadett Szabados Panel: Ananya Choudhury, Maria De Santis, Ignacio Duran, Petros Grivas, Dora Niedersüß-Beke, Peter Hoskin, Rob Jones, Daniele Raggi, Bernadett Szabados
	Case presentation - Daan De Maeseneer
	Are ADCs a better partner for IO than platinum-based chemotherapy? - Daniele Raggi
	Do real-world data confirm trial data of the new SOC in first line? - Dora Niedersüß-Beke
	Treatment sequencing in the era of combination therapies - Rob Jones
	Histological subtypes in the metastatic setting: what now? - Ananya Choudhury
	Panel discussion and Q&A
13:00	End of BLADDR

BLADDR thanks its sponsors and partners

Principal sponsor



Silver sponsors





Bronze sponsors









Exhibition sponsor









Partners













Practical information



General information Hanne Kraat +32 479 10 85 98 **Exhibitors & sponsors** Luc Van Ruysevelt +32 476 25 82 94

Opening hours registration & information desk

Tuesday 26 November: 10:00 - 18:00 Wednesday 27 November: 08:00 - 18:00 Thursday 28 November: 08:00 - 14:00

Accreditation points



RENALC 2024 - Global Forum on Renal cell Cancer (1st edition), Vienna & hybrid, Austria 26/11/2024, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **4.0** European CME credits

(ECMEC®).

BLADDR 2024 - Global Forum on Bladder Cancer (9th edition), Vienna & hybrid, Austria 27/11/2024-28/11/2024, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **10.0** European CME credits (ECMEC®).

Accreditation Statement: Each medical specialist should claim only those credits that he/she actually spent in the educational activity. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credits to AMA credits can be found at https://edhub.ama-assn.org/pages/applications. Live educational activities occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC® credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Certificate of attendance

- 1 Go to https://library.mirrorsmed.org and log in using your personal credentials you received by email.
- 2 Go to the section "My certificates" and download your certificate of attendance.

Certificate of accreditation

- 1 Go to https://library.mirrorsmed.org and log in using your personal credentials you received by email.
- 2 Go to the section "My certificates" and complete the evaluation form.
- **3** After completion, you can **download** your certificate of accreditation.
- ② Deadline to complete the evaluation form and download the certificate of accreditation: 31 May 2025.

















Every week a new case!

Join 4000 colleagues and see what they would do... and what the experts say!

Stay up-to-date about clinical advances in:

- **Ø** Bladder cancer
- Ø Renal cell carcinoma

Patient cases right into your mailbox!

- ∅ Compare with peers and experts
- ∅ Individual pathways with QuickScan







Why not join your colleagues...it's free!

ppcp.mirrorsmed.org

Notes

Notes Notes





ALL SESSIONS ARE INTERACTIVE



Ask the faculty all your questions and participate in interactive voting via your smartphone.

JOIN AT SLIDO.COM

#RENALC or SCAN



#BLADDR or SCAN

